Diabetes mellitus and cystic fibrosis: Comparison of clinical parameters in patients treated with insulin versus oral glucose‐lowering agents

Rosenecker, Joseph; Eichler, Irmgard; Bärmeier, Heike; Hardt, H. von der

doi:10.1002/ppul.1143

Cited by 47 publications

(29 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Metformin: causes, in most patients, intolerable collateral effects, such as nauseas, diarrhea and abdominal discomfort (60). Thiazolidinediones: were recently associated with osteoporosis.…”

Section: Therapy With Oral Agentsmentioning

confidence: 99%

Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD)

Noronha

Calliari

Damaceno

et al. 2011

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Cystic fibrosis (CF) is the most common recessive autosomal disease among Caucasian. Children with CF have benefitted from advances in medical and nutritional treatments, and this can be gleaned from the improvement in the survival of these patients. The increase in the survival rate brought with it the appearance of co-morbidities related to CF. Nowadays cystic fibrosis-related diabetes (CFRD) is considered the most common complication associated with CF. It can appear as early as infancy or adolescence, and its prevalence can be as high as 50% in adult patients. Because of its high prevalence, difficulties in early detection and the risks involved, in recent years several studies and consensuses have focused on this condition, adding information about the epidemiology, pathophysiology, prognosis and treatment of CFRD. The main aspects of these new concepts, as well as the current recommendations for its diagnosis and follow-up, will be presented in this study.

show abstract

Section: Therapy With Oral Agentsmentioning

confidence: 99%

Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD)

Noronha

Calliari

Damaceno

et al. 2011

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…These alterations can be observed 2-4 years before CFRD diagnosis (14). When overt diabetes is present, both insulin replacement and oral glucoselowering agents have proven to reverse negative changes in weight, nutritional status and pulmonary function (20,21). However, during pre-diabetic phases of this CF-related alteration of glucose metabolism, possible benefits of therapeutic interventions are not well established.…”

Section: Introductionmentioning

confidence: 99%

Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis

et al. 2005

View full text Add to dashboard Cite

Objective: To evaluate insulin-secretion kinetics and insulin sensitivity in cystic fibrosis (CF) patients with normal glucose tolerance (CF-NGT), impaired glucose tolerance (CF-IGT) or CF-related diabetes (CFRD), and the potential effects of moderate hyperglycemia on clinical and nutritional status. Design and methods: Cross-sectional study including 50 outpatients with CF. Patients underwent both oral (OGGT) and intravenous (IVGTT) glucose tolerance tests in order to assess insulin secretion and peripheral insulin sensitivity. Homeostasis assessment model and OGGT were used to investigate insulin sensitivity. Forced expiratory volume in the first second (FEV 1 ) and forced vital capacity (FVC) were measured to evaluate pulmonary function. Body mass index (BMI) was determined to assess nutritional status. Results: Insulin secretion was significantly decreased (and delayed at OGTT) in the CFRD group (n ¼ 9) versus the CF-IGT group (n ¼ 10) and the CF-IGT versus the CF-NGT group (n ¼ 31). Insulin sensitivity was significantly different in the CF-IGT and CFRD groups versus the CF-NGT group. FEV 1 , FVC and BMI presented a significant linear correlation with plasma glucose value at 120 min at OGTT and were significantly lower in both CF-IGT and CFRD versus the CF-NGT group, whereas no differences were found between the CF-IGT and CFRD groups. Conclusions: CF patients with IGT present diminished insulin secretion and increased peripheral insulin resistance, correlating with a worse clinical status, undernutrition and impaired pulmonary function. These findings open the question of whether early treatment of mild alterations of glucose metabolism with insulin secretagogues or short-action insulin may lead to improvement of clinical status in CF patients.European Journal of Endocrinology 152 241-247

show abstract

“…15,119,120 Adler et al 121 noted reductions in FEV 1 and FVC in both CFRD and CFIGT. It is concerning that this decline is seen from at least 2-4 years before diabetes is diagnosed using the standard OGTT.…”

mentioning

confidence: 99%

Screening for cystic fibrosis-related diabetes: a systematic review.

Waugh

Royle²,

Craigie³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects...

show abstract

Diabetes mellitus and cystic fibrosis: Comparison of clinical parameters in patients treated with insulin versus oral glucose‐lowering agents

Cited by 47 publications

References 23 publications

Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD)

Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD)

Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis

Screening for cystic fibrosis-related diabetes: a systematic review.

Contact Info

Product

Resources

About